Philippe LANGELLA

	Laboratory of Commensals and Probiotics-Host Interactions MICALIS Institute, INRA, Jouy en Josas France Tel : 33 1 34 65 20 70 Fax : 33 1 34 65 24 62 E-mail: philippe.langella@inra.fr
Born on May 31st 1958 Married, 3 kids

Research Director of First Class INRA

Deputy Director of the MICALIS Institute (INRA, Jouy en Josas) Head of the Food and Digestive Ecosystems Division  since January 2014

Director of the Laboratory of « Commensals and Probiotics-Host Interactions » (36 people including 8 scientists, 5 engineers and 5 technicians) since 2004

Deputy Director of Unit of Ecology and Physiology of Digestive tract (UEPSD) (2007-2009)

Responsible of “Probiotics” network of INRA

Visiting scientist at Farncombe Digestive Health Institute (McMaster University, ON, Canada) since July 2010

Career profile:

PhD obtained in 1988 in Rennes University, France.

Employed as a scientist in INRA (National Institute of Agricultural Research) since 1983: junior scientist (1983-1989), senior scientist (1989-1993), group leader (from 1993 to now).

Research Director INRA since January 2004.

Leader of the Laboratory of « Commensals and Probiotics-Host Interactions » (>35 persons) since October 2004.
One hundred and ninety-eight publications (182 primary articles and 16 reviews; h-index 45 in Web of Knowledge and 56 in Google Scholar citations) in peer-reviewed international journals.

Invited 65 times as lecturer and 40 selected oral presentations at international conferences.

Referees for several scientific publications as Applied and Environmental Microbiology, PLoS One, Gut, PNAS, Mucosal Immunology and Vaccine

Director of twenty-three PhD students and of twenty-one post-doctorants

Current Research activities:

I am Research Director at the French National Institute of Agricultural Research (INRA). I started to work on genetics of lactic acid bacteria (LAB) in 1983. Since 1993, my team has developed new uses of LAB as live delivery vehicles to improve human health. My most-achieved project concerns a new strategy to prevent and to fight against intestinal inflammatory pathologies using such recombinant LAB (recLAB; Science Translational Medicine, 2012).

Since 2004, I’m involved in both commensals and probiotics domains to better understand the mechanisms of these bacteria and to enhance their use in human and animal health. My main goal is to gain a better understanding of the crosstalk between these resident and transiting bacteria and the host in order to unravel the mechanisms of their beneficial effects on human health. I’m more particularly studying anti-inflammatory effects of commensals and probiotics in murine models. In 2008, my laboratory has identified the first anti-inflammatory commensal bacterium based on human clinical data (PNAS, 2008). I have authored 197 peer-reviewed international publications at the interface between microbiology and human health (WoK h-index 45). My laboratory is also leader in the use of recombinant probiotics to deliver molecules of health interest at the mucosal level and I recently patented such novel anti-inflammatory strains. I’m co-inventor of 17 patents in the domain of the use of commensal and probiotic bacteria in health domain. I have participated in numerous national and European research projects and have strong research collaborations with several agro-food and pharmaceutical companies. I’m a referee for many international journals and consulting expert for several agro-food and pharmaceutical companies.

Research grants obtained:

Most important research contracts (2001-2017):

19 public contracts for a total amount of € 5.2 millions (2001-2017):
- 9 ANR (~ 200 k€ per three-year contract for the team since 2006); 2 InCa (150 k€ for 2007-2010 and 2013-2015 € 200k), 4INRA [75 k€ PTR 2008-2010; 100 k€ as Young Team for 2006-2008 and 100 k€ INRA-transfer 2014 and 2016], 3 IDEX contracts (75 k€ each, one in 2013 and two in 2014], two of the European Community [900 k€ for poly-modE (2009-2012) and 500 k€ for Arylmmune], 2 of the Single Interministerial Fund (~ 600 k€ 2011-2008 contract and 2010-2013) and one of the Canadian Foundation for Crohn's disease (65 k€ 2010-2011 ).

26 industrial contracts for a total amount of € 3.5 millions (2004-2017):
- 14 contracts with food companies: 1 contract with Nestlé (40 k€ in 2006); 4 contracts with Syndifrais (~ 45 k€ 2004 contract to 2009); 1 contract with Soufflet (300 k€ in 2009/2010), 1 contract with Lactalis (150 k€ in 2009-2010); 2 contracts with Biose (120 k€ in 2012-2015 and 160 k€ in 2016); 4 contracts with Danone (750 k€: 1 in 2009-2011 and three in 2013-2017) and 2 contracts with Lallemand in 2017 (250 k€).
- 12 contracts with pharmaceutical companies: 3 contracts with Biocodex (70 k€ in 2008 and 300 k€ in 2012 and 2015) and one contract with Ferring (20 k€ in 2008); 1 contract with Boehringer -Ingelheim (50 k€ in 2009/2010), 1 contract with Servier (120 k€ in 2010), 1 contract with Merck Medication (€ 80 thousand in 2014), 1 contract with Symbiopharm (180 k€ for 2014-2015), 1 contract with Enterome (180 k€ for 2015-2016), 1 contract with Merial (100 k€ for 2016); 1 contract with Pilèje (200 k€ in 2016-2017) and one contract with Merck Serono (200 k€ for 2010-2012).

44 academic PhD and post-doctoral grants (1993-2017):

23 PhD grants (~105 k€ per thesis): 6 from MENRT, 2 from INRA, 5 industrials, 1 from tunisian government, 2 from CAPES (Brazil) and 6 from EC. 21 post-doctoral grants (50 k€ per year and per grant) (1999-2010): 8 from CAPES (Brazil), 1 from Ile-de-France region, 4 from MENRT, 1 from INRA, 1 from ARC, 2 from industrial contracts and 3 from FUI.

Teaching and expertises activities:

Teaching: Thirty hours of lessons on lactic acid bacteria and probiotics in engineer schools (AgroParisTech, AgroSup Dijon and SupAgro Rennes) and in Universities [Paris VI and XI, Grenoble, Tours and Belo Horizonte (Brazil)] since 2004.

Supervisor: supervisor or co-supervisor of 23 PhD students since 1993, of 21 post-doctorants and ~20 BTS, Licence or Master students.

Referees or examinator in 24 PhD juries and in 3 HDR juries in France and in Denmark

Scientific expertise for scientific journals as Applied and Environmental Microbiology, Microbiology, Cancer Research, PNAS, Microbes and Infection and Vaccine

Scientific industrial expertise: for the following companies Rosell-Lallemand (Toulouse), Johnson&Johnson (USA), Merck-Serono (Suisse), Merck-Médication Familiale (Dijon), Gate2Tech (Nantes), Metagenics (Bruxelles, Belgique), Biose (Clermont-Ferrand) and ViThera (USA)

Other activities:

Co-founder and co-leader with G. Corthier of the INRA Probiotics Network

Organiser of three Symposia on Probiotics in May 2006, June 2008 and May 2010 (100 participants)

Evaluation of research projects for INRA, ANR, Centre region, Norway and Denmark

Member of a Specialised Scientific Commission INRA (CSS SAMSAGP, 2003-2007)

Member of several evaluation committees of INRA laboratories and recruitment juries for scientists, engineers and teachers.

Major recent publications (2008-2017):

1. Martín R, Chain F, Miquel S, Motta JP, Vergnolle N, Sokol H, Langella P. Using murine colitis models to analyze probiotics-host interactions. FEMS Microbiol Rev. 2017 Aug 1;41(Supp_1):S49-S70.

2. Martín R, Bermúdez-Humarán LG, Langella P. Searching for the Bacterial Effector: The Example of the Multi-Skilled Commensal Bacterium Faecalibacterium prausnitzii. Front Microbiol. 2018 Mar 6;9:346.

3. .Remot A, Descamps D, Noordine ML, Boukadiri A, Mathieu E, Robert V, Riffault S, Lambrecht B, Langella P, Hammad H, Thomas M. Bacteria isolated from lung modulate asthma susceptibility in mice. ISME J. 2017 Jan 3.

4. Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, Brot L, Taleb S, Couturier-Maillard A, Nion-Larmurier I, Merabtene F, Seksik P, Bourrier A, Cosnes J, Ryffel B, Beaugerie L, Launay JM, Langella P, Xavier RJ, Sokol H. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptorligands. Nat Med. 2016 Jun;22(6):598-605.

5. Hoffmann TW, Pham HP, Bridonneau C, Aubry C, Lamas B, Martin-Gallausiaux C, Moroldo M, Rainteau D, Lapaque N, Six A, Richard ML, Fargier E, Le Guern ME, Langella P, Sokol H. Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice. ISME J. 2016 Feb;10 (2):460-77.

6. Quévrain E, Maubert MA, Michon C, Chain F, Marquant R, Tailhades J, Miquel S, Carlier L, Bermúdez-Humarán LG, Pigneur B, Lequin O, Kharrat P, Thomas G, Rainteau D, Aubry C, Breyner N, Afonso C, Lavielle S, Grill JP, Chassaing G, Chatel JM, Trugnan G, Xavier R, Langella P, Sokol H, Seksik P. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut. 2016 Mar;65(3):415-25

7. Miquel S, Leclerc M, Martin R, Chain F, Lenoir M, Raguideau S, Hudault S, Bridonneau C, Northen T, Bowen B, Bermúdez-Humarán LG, Sokol H, Thomas M, Langella P. Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. MBio. 2015 Apr 21;6 (2).

8. Bermúdez-Humarán LG, Aubry C, Motta JP, Deraison C, Steidler L, Vergnolle N, Chatel JM, Langella P. Engineering lactococci and lactobacilli for human health. Curr Opin Microbiol. 2013 Jul 11.

9. Miquel S, Martín R, Rossi O, Bermúdez-Humarán L, Chatel J, Sokol H, Thomas M, Wells J, Langella P. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2013 Jul 3.

10. Wrzosek L, Miquel S, Noordine ML, Bouet S, Chevalier-Curt MJ, Robert V, Philippe C, Bridonneau C, Cherbuy C, Robbe-Masselot C, Langella P, Thomas M. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol. 2013 May 21;11:61.

11. Motta JP, Bermúdez-Humarán LG, Deraison C, Martin L, Rolland C, Rousset P, Boue J, Dietrich G, Chapman K, Kharrat P, Vinel JP, Alric L, Mas E, Sallenave JM, Langella P, Vergnolle N. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med. 2012 Oct.

13. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008 Oct 28;105 (43):16731-6.